(Dharshini.G, Intern journalist) New Delhi: A Delhi-based private research center, Dr. Dangs Lab, has confirmed that it has been chosen as the main lab for human clinical preliminaries of Covaxin, India’s indigenous COVID-19 immunization applicant. The antibody is being created and made by Bharat Biotech as a team with the Indian Council of Medical Research (ICMR) and the National Institute of Virology(NIV) Pune.

“We are happy to announce that Dr. Dangs Lab, New Delhi has been given the chance to serve the country by being chosen as the main lab for the Human Clinical trials of Covaxin; India’s indigenous¬†COVID-19¬†vaccine being created and made by Bharat Biotech in a joint effort with the ICMR, NIV,” Dr. Dang’s Lab said in an announcement.

This is a “randomized, double-blind,placebo-controlled multi-centric clinical trial in India”, it included.”Dr. Dangs Lab is presently handling all examples for screening and wellbeing for the different periods of this clinical trial, though all the viability studies will be performed in NIV,” the announcement said.

The lab has just begun getting tests from 50 to 100 subjects for each day from different trial sites for safety testing and will be expanding activities according to the assigned timeline of events to cover 12 locales over the length and breadth of the nation over this month.